News Sentiment

INDV sentiment intelligence

Indivior PLC Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 62 Constructive news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 40.50 Week of 10 Jul 2026
Weighted tone 62/100

Constructive news tone

Market reaction News confirmed by price

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update

82/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+1.8% over one week, +5.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

INDIVIOR PHARMACEUTICALS INC (NASDAQ:INDV) Shows Breakout Setup With Perfect Technical Strength Score

Market Reaction

News confirmed by price

73/100 confidence

Constructive news tone is being confirmed by positive weekly price action.

Primary event Market update 82/100 classification
One-week reaction 1.8% Price digesting
Trend fit Trend active 5.2% over four weeks
Fair value 98.8% Materially above fair value
Sentiment confirms active trend Positive but stretched

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 30
Neutral 20
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
AD HOC NEWS 9
TradingKey 5
Ad-hoc-news.de 4
Quartr 3
ChartMill 2
Ad Hoc News 2
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 9
Regulatory and legal 3
Guidance 3
Macro sensitivity 2
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
Ad Hoc News Direct company coverage

Indivior stock trades steady as opioid treatment specialist focuses on growth after recent earnings

Indivior's stock performance is influenced by the balance between its growing opioid use disorder treatment sales and ongoing legal settlement costs. The company's recent earnings show strong revenue growth driven by its flagship opioid use disorder therapies, with profitability

Tone
Positive 65/100
Event
Earnings
Published
17 Jul 2026 04:10
Source
Ad Hoc News
Ad Hoc News Direct company coverage

Indivior stock holds steady as addiction-treatment strategy stays in focus

Indivior stock reflects the company's focus on addiction therapies, particularly opioid use disorder, positioning it within long-term healthcare trends. The company's strategy involves expanding treatment options, operating within a heavily regulated environment, and facing compe

Tone
Positive 66/100
Event
Market update
Published
16 Jul 2026 05:40
Source
Ad Hoc News
Quartr Direct company coverage

Indivior (INDV) Q4 2025 earnings summary

Indivior (INDV) reported record SUBLOCADE net revenue of $856M in 2025, up 13% year-over-year, contributing to total net revenue of $1.24B. Adjusted EBITDA grew 20% to $428M, with a significant margin improvement. The company also resolved a DOJ matter for $295M and authorized a

Tone
Positive 77/100
Event
Earnings
Published
14 Jul 2026 10:17
Source
Quartr
Quartr Direct company coverage

Indivior (INDV) Morgan Stanley 23rd Annual Global Healthcare Conference Summary

Indivior presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, focusing on its "Action Agenda" with SUBLOCADE as the main growth driver. The company detailed efforts in organizational simplification, cost reduction, and improving commercial execution, especial

Tone
Positive 64/100
Event
Market update
Published
09 Jul 2026 06:17
Source
Quartr
Quartr Direct company coverage

Indivior (INDV) Q4 2024 earnings summary

Indivior (INDV) reported a 9% increase in FY 2024 net revenue to $1,188m, driven by a 20% rise in SUBLOCADE net revenue. The company achieved a 16% increase in adjusted operating profit and expanded its SUBLOCADE patient base by 25%. For FY 2025, Indivior anticipates a total net

Tone
Positive 65/100
Event
Earnings
Published
08 Jul 2026 18:12
Source
Quartr
AD HOC NEWS Direct company coverage

Indivior PLC outlines its addiction treatment focus as investors weigh long-term growth

Indivior PLC is a specialty pharmaceutical company focused on addiction treatment, particularly opioid use disorder, with a business model centered on prescription medicines. The United States is a critical market for the company due to the scale of the opioid crisis, though it a

Tone
Positive 64/100
Event
Market update
Published
08 Jul 2026 07:34
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Indivior PLC focuses on addiction therapies as investors watch long term growth

Indivior PLC, a specialty pharmaceutical company, is concentrating on addiction treatment, particularly for opioid use disorder. Investors are closely monitoring its pipeline, global market presence, and the regulatory environment. The company's business model relies on prescript

Tone
Positive 65/100
Event
Regulatory and legal
Published
07 Jul 2026 14:13
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Indivior stock leans on its core addiction treatment business

Indivior's stock performance is primarily driven by its addiction treatment portfolio, particularly for opioid use disorder. The London-listed company has a strong focus on the US market and its shares are influenced by product uptake, regulatory changes, and reimbursement condit

Tone
Neutral 50/100
Event
Regulatory and legal
Published
07 Jul 2026 07:13
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Sublocade from Indivior - once-monthly injection reshapes US opioid treatment

Indivior's Sublocade, a once-monthly injection of buprenorphine, is transforming opioid use disorder treatment in the US by offering a stable, long-acting option for patients. This FDA-approved medication helps reduce daily decision-making for patients and is a strategic growth p

Tone
Positive 72/100
Event
Market update
Published
06 Jul 2026 07:40
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Indivior PLC updates investors on business strategy. Focus on addiction treatment portfolio

Indivior PLC has updated investors on its long-term business strategy, emphasizing its leadership in addiction treatment, particularly for opioid use disorder. The strategy involves expanding its product portfolio, growing its global footprint, and investing in R&D, while also fo

Tone
Positive 71/100
Event
Market update
Published
05 Jul 2026 11:10
Source
AD HOC NEWS
Ad-hoc-news.de Direct company coverage

Indivior PLC outlines long-term strategy as addiction treatments remain in demand

Indivior PLC is focusing on expanding its portfolio of addiction treatments, particularly for opioid dependence, by investing in R&D for new formulations and delivery mechanisms. The company operates in a field influenced by evolving regulation and reimbursement policies, emphasi

Tone
Positive 67/100
Event
Macro sensitivity
Published
04 Jul 2026 09:40
Source
Ad-hoc-news.de
Ad-hoc-news.de Direct company coverage

Indivior stock holds the focus. US listing and product model frame the setup.

Indivior PLC maintains a clear US-market profile with its Nasdaq listing and focus on addiction treatment pharmaceuticals, specifically for opioid use disorder. The company's business model relies on specialty medicines like SUBLOCADE, driven by treatment access and prescription

Tone
Positive 64/100
Event
Market update
Published
03 Jul 2026 19:40
Source
Ad-hoc-news.de
Ad-hoc-news.de Direct company coverage

Indivior navigates addiction-treatment demand. Investors weigh long-term growth prospects

Indivior PLC, a specialty pharmaceutical company, operates at the intersection of addiction science and medicine, focusing on opioid-use disorder and related mental health conditions. The article examines how investors are evaluating its growth plans, product portfolio, and regul

Tone
Positive 63/100
Event
Macro sensitivity
Published
03 Jul 2026 10:39
Source
Ad-hoc-news.de
Ad-hoc-news.de Direct company coverage

Indivior consensus shapes expectations, shares on Nasdaq under analyst scrutiny

Indivior's Nasdaq listing is under analyst scrutiny, with a clear consensus forming around its earnings and valuation. This analysis focuses on how forecasts, ratings, and the sector context influence the risk-reward profile for retail investors. The company, known for its bupren

Tone
Positive 61/100
Event
Earnings
Published
28 Jun 2026 11:11
Source
Ad-hoc-news.de
Kavout | AI Direct company coverage

Is Big Pharma's Patent Cliff Driving a New M&A Wave

The pharmaceutical industry is facing a significant "patent cliff" by 2032, driving a new wave of M&A activity as major pharma companies seek to acquire innovative assets to offset potential revenue losses. Indivior (INDV), specializing in buprenorphine-based addiction treatments

Tone
Positive 66/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
Kavout | AI
TradingView Direct company coverage

Reasons Why Investors Should Consider Betting on Indivior Stock

Indivior (INDV) is positioned as a strong investment due to the commercial success of its Sublocade treatment for opioid use disorder, with management anticipating accelerated U.S. dispense-unit growth. The company also demonstrates disciplined capital allocation by focusing on h

Tone
Positive 72/100
Event
Market update
Published
25 Jun 2026 13:09
Source
TradingView
Investing.com Direct company coverage

Indivior stock reaches all-time high at 41.09 USD

Indivior PLC's stock has hit an all-time high of $41.09, reflecting a 197.82% increase over the past year and suggesting the shares are slightly undervalued according to InvestingPro analysis. This surge is attributed to strong financial performance, strategic initiatives, aggres

Tone
Positive 94/100
Event
Market update
Published
24 Jun 2026 15:40
Source
Investing.com
Investing.com Nigeria Direct company coverage

Form 4 Indivior PLC For: 23 June By Investing.com

This article simply states that Form 4 for Indivior PLC for June 23 has been published by Investing.com. It provides no further details about the Form 4 itself, but includes various financial market data and popular news headlines as context on the publishing platform.

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 23:09
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Indivior Pharmaceuticals (INDV) CEO vests 1.27M shares, 612K for taxes

Indivior Pharmaceuticals' CEO, Joseph Ciaffoni, had 1,266,903 performance stock units vest on June 22, 2026, after 100% of performance conditions were met. To cover tax withholding obligations, 612,549 of these shares were withheld, resulting in Ciaffoni directly holding 790,330

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 21:24
Source
Stock Titan
AD HOC NEWS Direct company coverage

Indivior - Weekly outlook on earnings and strategy

This article provides an outlook on Indivior's upcoming week, highlighting the absence of new market-moving headlines and focusing investor attention on the earnings calendar, legal settlements, and strategy in opioid use disorder treatments. It details how the company generates

Tone
Neutral 50/100
Event
Earnings
Published
22 Jun 2026 09:00
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Indivior Stock - Sunday background on the addiction-treatment specialist

This article provides a Sunday background on Indivior, a UK-based addiction-treatment specialist, focusing on its corporate history, product portfolio, and regulatory landscape. Since there's no fresh weekend news, it offers retail investors a structured overview of the company's

Tone
Neutral 50/100
Event
Regulatory and legal
Published
21 Jun 2026 05:09
Source
AD HOC NEWS
TradingKey Direct company coverage

Indivior PLC (INDV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Indivior PLC (INDV), focusing on its regional contributions. As of the specified data, the United States accounts for 85.03% of the company's revenue, totaling $267.00 million, while the Rest of World contributes 14.97% or $47.00 mill

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 20:40
Source
TradingKey
AD HOC NEWS Direct company coverage

Why Indivior’s Once?Monthly Sublocade shot is changing opioid treatment routines

Indivior's Sublocade is a once-monthly, extended-release buprenorphine injection designed to treat opioid use disorder, offering an alternative to daily pills. This treatment aims to provide stable buprenorphine levels, reducing daily dosing burden and diversion risk, though it r

Tone
Positive 70/100
Event
Market update
Published
19 Jun 2026 07:13
Source
AD HOC NEWS